Design Therapeutics, Inc. Debt Conversion, Original Debt, Amount
Design Therapeutics, Inc. (DSGN) reported Debt Conversion, Original Debt, Amount of $500.00 thousand for the 1-month period ending 2020-02-29, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2022-03-10
- 2020-02-29: Debt Conversion, Original Debt, Amount 1 month $500.00K.
| Period end | Debt Conversion, Original Debt, Amount 1 month |
|---|---|
| 2020-02-29 | $500.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |